- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: Therapeutic Use Exemption.
Displaying page 1 of 1.
EudraCT Number: 2006-006537-40 | Sponsor Protocol Number: VEG108838 | Start Date*: 2008-01-22 | |||||||||||
Sponsor Name:GlaxoSmithkline Research & Development Limited | |||||||||||||
Full Title: A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer | |||||||||||||
Medical condition: Relapsed or refractory inflammatory breast cancer with ErbB2 tumours. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) IT (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000625-12 | Sponsor Protocol Number: CTMX-M-2009-001 | Start Date*: 2018-02-15 | |||||||||||
Sponsor Name:CytomX Therapeutics, Inc | |||||||||||||
Full Title: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Lo... | |||||||||||||
Medical condition: Metastatic or locally advanced unresectable solid tumors in following indications: breast cancer (BC), castrate-resistant prostate carcinoma (CRPC), non-small cell lung carcinoma (NSCLC), ovarian... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005912-28 | Sponsor Protocol Number: EGF107671 | Start Date*: 2007-04-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd. | |||||||||||||
Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi... | |||||||||||||
Medical condition: Brain metastases from ErbB2-positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
